Guangji Pharmaceutical: It is expected that the net profit attributable to the mother in 2025 will be a loss of 518 million to 399 million yuan.

Guangji Pharmaceutical announced that it is expected to record a net loss attributable to shareholders of 518 million to 399 million yuan in 2025, compared to a loss of 295 million yuan in the same period last year. During the reporting period, the company's main product sales prices remained low due to continued intensifying competition in the industry, failing to show signs of recovery. In this context, the company's capacity utilization and overall operating performance did not meet expectations, leading to the company remaining in an operating loss position during the reporting period.